Zika Vaccines Market - Global Industry
Insights, Trends, Outlook, and Opportunity
Analysis, 2018–2026
Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus.
This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also
be transmitted through blood transfusion, sexual contact or from infected pregnant women to the
fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only
1 in 4 people with zika infection are prone to develop symptoms. In November 2016, the World
Health Organization (WHO) declared that zika infection no longer constitutes a Public Health
Emergency of International Concern (PHEIC) as major cases of zika virus were asymptomatic.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/413
In April 2015, a major ongoing outbreak of Zika virus was registered in Brazil, which later affected
the population in South and Central America. This outbreak caused mild illness (fever, rashes, joint
pains, conjunctivitis, nausea, and muscle pain), though the recent outbreaks showed severe
complications such as microcephaly, Guillain-Barré syndrome, and various congenital neurological
abnormalities in infants who were born to infected mothers. The link between zika virus and
microcephaly and Guillain-Barré syndrome was identified and reported in 2015 in Brazil.
According to the Centers for Disease Control and Prevention (CDC), 70 new zika virus infection
cases were reported in the U.S. in 2015, which increased to 41,181 cases in 2016. Lack of reporting
is a major factor for lower incidence rate in 2015. Increase in awareness can result in more
diagnosis and reporting thus generating growth of the global zika vaccines market.